{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:55:18Z","timestamp":1791179718780,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.drugalcdep.2009.02.007","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T08:28:11Z","timestamp":1237883291000},"page":"S9-S13","source":"Crossref","is-referenced-by-count":45,"special_numbering":"S1","title":["Risk management of drug products and the U.S. Food and Drug Administration: Evolution and context"],"prefix":"10.1016","volume":"105","author":[{"given":"Deborah B.","family":"Leiderman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2009.02.007_bib1","unstructured":"Drug Enforcement Administration, 2008. Prescription Drug Monitoring Programs. http:\/\/www.deadiversion.usdoj.gov\/faq\/rx_monitor.htm (accessed December 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib2","unstructured":"European Medicines Agency, 2005. Guideline on Risk Management Systems for Medicinal Products for Human Use. EMEA http:\/\/www.emea.europa.eu\/pdfs\/human\/euleg\/9626805en.pdf (accessed December 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib3","unstructured":"Food and Drug Administration, 1998. Actiq Approval Letter. http:\/\/www.fda.gov\/Cder\/foi\/appletter\/1998\/20747ltr.pdf (accessed December 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib4","unstructured":"Food and Drug Administration, 2002a. Xyrem (sodium oxybate): Questions and Answers. http:\/\/www.fda.gov\/cder\/drug\/infopage\/xyrem\/xyrem_qa.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib5","unstructured":"Food and Drug Administration, 2002b. Lotronex (alosetron hydrochloride) Information. FDA http:\/\/www.fda.gov\/cder\/drug\/infopage\/lotronex\/lotronex.htm (accessed December 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib6","unstructured":"Food and Drug Administration, 2002c. Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride). http:\/\/www.fda.gov\/cder\/drug\/infopage\/subutex_suboxone\/default.htm (accessed December 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib7","unstructured":"Food and Drug Administration, 2003. CDER\/CBER Risk Management Public Workshop. FDA http:\/\/www.fda.gov\/cder\/meeting\/riskManagement.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib8","unstructured":"Food and Drug Administration, 2005a. Guidance for Industry on the Development and Use of Risk Minimization Action Plans, http:\/\/www.fda.gov\/cder\/guidance\/6358fnl.htm (accessed November 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib9","unstructured":"Food and Drug Administration, 2005b. Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. http:\/\/www.fda.gov\/cber\/gdlns\/pharmacovig.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib10","unstructured":"Food and Drug Administration, 2005c. Guidance for Industry Premarketing Risk Assessment. http:\/\/www.fda.gov\/CDER\/guidance\/6357fnl.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib11","unstructured":"Food and Drug Administration, 2006. iPLEDGE Update. http:\/\/www.fda.gov\/cder\/drug\/infopage\/accutane\/iPLEDGEupdate200603.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib12","unstructured":"Food and Drug Administration, 2007a. Workshop announcement: Implementation of Risk Minimization Action Plans (RiskMAPs) to Support Quality Use of Pharmaceuticals: Opportunities and Challenges. http:\/\/www.fda.gov\/cder\/meeting\/riskMAPs.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib13","unstructured":"Food and Drug Administration, 2007b. Law Strengthens FDA. http:\/\/www.fda.gov\/oc\/initiatives\/advance\/fdaaa.html (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib14","unstructured":"Food and Drug Administration, 2008a. Medication Guides. http:\/\/www.fda.gov\/cder\/Offices\/ODS\/medication_guides.htm (accessed December 11, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib15","unstructured":"Food and Drug Administration, 2008b. Federal Register: Identification of Drugs Deemed to have REMS. Federal Register 73 (60) March 27, 2008. http:\/\/www.fda.gov\/OHRMS\/DOCKETS\/98fr\/E8-6201.pdf (accessed November 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib16","unstructured":"Food and Drug Administration, 2008c. FDAAA Q and A: March 26, 2008. http:\/\/www.fda.gov\/cder\/regulatory\/FDAAA\/FR_QA.htm (accessed November 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib17","unstructured":"General Accounting Office, 2003, Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. GAO-04-110, 58 p., and GAO http:\/\/www.gao.gov\/new.items\/d04110.pdf (accessed December 12, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib18","series-title":"Pharmaceutical Risk Management: Practical Applications","first-page":"11","article-title":"Risk management of pharmaceutical products at the FDA-A historical perspective","author":"Leiderman","year":"2008"},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib19","unstructured":"Trontell, A., 2002. Evolving Perspectives on Managing the Risks of Medical Products. FDA http:\/\/www.fda.gov\/cder\/present\/raps10-2002\/annetrontell\/sld001.htm (accessed August 1, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.02.007_bib20","unstructured":"von Eschenbach, A.C., 2008. The FDA Amendments Act: Reauthorization of the FDA. http:\/\/www.fda.gov\/oc\/speeches\/2008\/fdli032608.html (accessed December 12, 2008)."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871609000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871609000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T22:50:55Z","timestamp":1545346255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871609000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":20,"alternative-id":["S0376871609000544"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.02.007","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}